Growth Hormone Axis Research blend
Tesamorelin + Ipamorelin TI
GHRH + GHS blend
Research blend of tesamorelin, a stabilised GHRH analogue, and ipamorelin, a ghrelin-receptor agonist, studied for growth hormone release.
Evidence level. Evidence comes mainly from animal or other preclinical models. For a blend, the rating covers the combination itself; each component has its own profile. About the badges
- Class
- GHRH + GHS blend
- Category
- Growth Hormone Axis
- Type
- Research blend
- Abbreviation
- TI
- Development and regulatory status
- Not approved; research blend of an approved drug and an investigational peptide
Blend composition
Tesamorelin 10 mg + Ipamorelin 5 mg (15 mg); Tesamorelin 11 mg + Ipamorelin 6 mg (17 mg)
Each component is profiled separately in the catalogue: Tesamorelin, Ipamorelin, CJC-1295 (no DAC) + Ipamorelin.
What researchers study
Two-component research blend of tesamorelin, a stabilised GHRH analogue, and ipamorelin, a ghrelin-receptor (GHS-R1a) agonist. The components act through different pituitary receptors, so the blend is studied for combined effects on growth hormone release.
Research areas
- Combined GHRH and ghrelin-receptor pathway studies
- GH axis responses to two secretagogue mechanisms
- Analytical characterisation of two-peptide blends
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- phase 3 trial
Tesamorelin alone reduced visceral fat by 15.2% versus a 5.0% rise with placebo over 26 weeks in 412 adults with HIV and abdominal fat
- rodent and swine
Ipamorelin alone released GH in rats and swine with potency similar to GHRP-6
- no data
No peer-reviewed study of the combination itself was identified in this search
Studied alongside
Compounds that appear together in research because their mechanisms complement each other, or as comparators. The reasons given are research reasoning, not recommendations for use.
- TesamorelinGHRH-analogue component of the blend
- Ipamorelinghrelin-receptor agonist component of the blend
- CJC-1295 (no DAC) + Ipamorelinanalogous GHRH-analogue plus ghrelin-receptor agonist blend
